{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:57:48Z","timestamp":1790387868495,"version":"4.1.0"},"reference-count":20,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center Support","award":["2024\/GNT2033412"],"award-info":[{"award-number":["2024\/GNT2033412"]}]},{"name":"NIH\/NCI Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nivolumab plus ipilimumab (COMBO) is the standard treatment for asymptomatic melanoma brain metastases (MBM), but current guidelines do not provide specific recommendations for treatment discontinuation in responding patients. This study aimed to evaluate outcomes after COMBO discontinuation within 24 months and the role of continuing treatment beyond 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with MBM treated with COMBO who discontinued treatment within 24 months for reasons other than disease progression or continued beyond this time point were retrieved. Overall survival (OS), objective response, progression-free survival (PFS) and toxicities were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>465 patients were included: 392 discontinued COMBO within 24 months, while 73 continued beyond 24 months. Treatment was discontinued due to complete response (CR, n=47), partial response (PR, n=45), stable disease (SD, n=12), toxicity after SD (n=59), toxicity after CR (n=99), or toxicity after PR (n=130). At multivariable analysis, the line of treatment (&gt;first vs first: HR 2.65 (1.62\u20134.32)), the immune-related adverse events (irrespective of anti-tumor necrosis factor-alpha) (HR 0.18 (0.07\u20130.42)); COMBO discontinuation after CR (HR 0.15 (0.05\u20130.40)), or PR (HR 0.08 (0.03\u20130.26)), as well as stopping due to toxicity after CR (HR 0.14 (0.07\u20130.27)) or PR (HR 0.51 (0.32\u20130.82)), were associated with OS. Notably, at a median follow-up of 51 months (IQR 31\u201370), patients with CR\/PR who discontinued COMBO within 24 months had PFS and OS comparable to those who continued treatment beyond this time point. 4-year OS exceeded 83% in patients discontinuing COMBO after CR, PR, or toxicity following CR, compared with 66.4% in those discontinuing due to toxicity after PR; median PFS was not reached in the former groups but was 18.6 months in the toxicity after PR group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Discontinuation of COMBO within 24 months appears safe in patients with CR and in selected cases of PR, with no survival disadvantage versus prolonged therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015063","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:23Z","timestamp":1777914923000},"page":"e015063","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02460068","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03340129","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-8959","authenticated-orcid":false,"given":"Mario","family":"Mandal\u00e0","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica F","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Sergi","sequence":"additional","affiliation":[{"name":"San Paolo Hospital, Bari, Apulia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael","family":"Postow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha R","family":"Lawless","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Effiom","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peres","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Lorigan","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Serra-Bellver","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[{"name":"Dermato-Oncology, Eberhard Karls Universitat Tubingen, Tubingen, Germany"},{"name":"ICANS, Strasbourg, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0173-9985","authenticated-orcid":false,"given":"Marie-Lena","family":"Rasch","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eberhard Karls Universitat Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-1195","authenticated-orcid":false,"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Vitale","sequence":"additional","affiliation":[{"name":"National Cancer Institute IRCCS Pascale Foundation, Naples, Campania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ubaldi","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-4106","authenticated-orcid":false,"given":"Alice","family":"Indini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn P M","family":"Suijkerbuijk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Utrecht University, Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carter","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-5903","authenticated-orcid":false,"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Medische Oncologie, Vrije Universiteit Brussel, Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-8906","authenticated-orcid":false,"given":"Ines","family":"Pires da Silva","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"Champalimaud Foundation, Lisbon, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander Maxwell","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Dermatology, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Dermatology, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Depenni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"K\u00e4hler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Schleswig Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Schleswig Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Genoa National Institute for Cancer Research, Genoa, Liguria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-1957","authenticated-orcid":false,"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Merelli","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Torino, Piemonte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Rossi","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore - Campus di Roma, Rome, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tucci","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University of Bari, Policlinico Hospital of Bari, Bari, Puglia, Italy"},{"name":"IRCCS Ospedale Oncologico di Bari Giovanni Paolo II, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-0319","authenticated-orcid":false,"given":"Michele","family":"Guida","sequence":"additional","affiliation":[{"name":"Oncology Department, Giovanni Paolo II Cancer Institute IRCCS, Bari, Apulia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"},{"name":"Federico II University Hospital, Naples, Campania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050410151676000_14.5.e015063.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00545-3"},{"key":"2026050410151676000_14.5.e015063.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"2026050410151676000_14.5.e015063.3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026050410151676000_14.5.e015063.4","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.1016\/j.ejca.2024.113531","article-title":"Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial","volume":"199","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026050410151676000_14.5.e015063.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32375"},{"key":"2026050410151676000_14.5.e015063.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"2026050410151676000_14.5.e015063.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026050410151676000_14.5.e015063.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.004"},{"key":"2026050410151676000_14.5.e015063.9","first-page":"v121","article-title":"The microenvironment of brain metastases from solid tumors","volume":"3","author":"Srinivasan","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026050410151676000_14.5.e015063.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026050410151676000_14.5.e015063.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.006"},{"key":"2026050410151676000_14.5.e015063.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115153"},{"key":"2026050410151676000_14.5.e015063.13","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050410151676000_14.5.e015063.14","doi-asserted-by":"crossref","first-page":"113542","DOI":"10.1016\/j.ejca.2024.113542","article-title":"Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study","volume":"199","author":"Mandal\u00e0","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026050410151676000_14.5.e015063.15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142559","article-title":"Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases-A Danish Real-World Cohort","volume":"16","author":"Kattenh\u00f8j","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026050410151676000_14.5.e015063.16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2021.02.037","article-title":"Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response","volume":"149","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026050410151676000_14.5.e015063.17","unstructured":"Common terminology criteria for adverse events (CTCAE), version 4.03. US Department of Health and Human Services. National Institutes of Health National Cancer Institute; 2010."},{"key":"2026050410151676000_14.5.e015063.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"2026050410151676000_14.5.e015063.19","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1200\/JCO.2017.35.15_suppl.9523","article-title":"Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL)","volume":"35","author":"Weber","year":"2017","journal-title":"JCO"},{"key":"2026050410151676000_14.5.e015063.20","doi-asserted-by":"crossref","first-page":"108069","DOI":"10.1016\/j.lungcan.2024.108069","article-title":"Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study","volume":"199","author":"Weller","year":"2025","journal-title":"Lung Cancer (Auckl)"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:25Z","timestamp":1777914925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2026-015063"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015063","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}